pharmacopeia
GET
/api/v1/drug/quinapril
2D structure
(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
SMILES CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O
InChIKey JSDRRTOADPPCHY-HSQYWUDLSA-N

Mechanism of action

Sourced from openFDA

Mechanism-of-action classes: Angiotensin-converting Enzyme Inhibitors; Neprilysin Inhibitors.

Angiotensin-converting EnzymeNeprilysin

Indications

Sourced from openFDA
  • Hypertension Quinapril tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.ICD-10: I10

Contraindications

Sourced from openFDA
  • Quinapril tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Quinapril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril).contraindicated

Dosage & administration

Sourced from openFDA

Hypertension Monotherapy: The recommended initial dosage of quinapril in patients not on diuretics is 10 or 20 mg once daily. Dosage should be adjusted according to blood pressure response measured at peak (2–6 hours after dosing) and trough (predosing). Generally, dosage adjustments should be made at intervals of at least 2 weeks. Most patients have required dosages of 20, 40, or 80 mg/day, given as a single dose or in two equally divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients an increase in dosage or twice daily administration may be warranted. In general, doses of 40–80 mg and divided doses give a somewhat greater effect at the end of the dosing interval. Concomitant Diuretics: If blood pressure is not adequately controlled with quinapril monotherapy, a diuretic may be added. In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally can occur following the initial dose of quinapril. To reduce the likelihood of hypotension, the diuretic should, if possible, be discontinued 2 to 3 days prior to beginning therapy with quinapril (see WARNINGS ). Then, if blood pressure is not controlled with quinapril alone, diuretic therapy should be resumed. If the diuretic cannot be discontinued, an initial dose of 5 mg quinapril should be used with careful medical supervision for several hours and until blood pressure has stabilized.

Warnings & precautions

Sourced from openFDA

FETAL TOXICITY • When pregnancy is detected, discontinue quinapril as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity

Adverse reactions

Sourced from openFDA

Hypertension Quinapril has been evaluated for safety in 4960 subjects and patients. Of these, 3203 patients, including 655 elderly patients, participated in controlled clinical trials. Quinapril has been evaluated for long-term safety in over 1400 patients treated for 1 year or more. Adverse experiences were usually mild and transient. In placebo-controlled trials, discontinuation of therapy because of adverse events was required in 4.7% of patients with hypertension. Adverse experiences probably or possibly related to therapy or of unknown relationship to therapy occurring in 1% or more of the 1563 patients in placebo-controlled hypertension trials who were treated with quinapril are shown below. Adverse Events in Placebo-Controlled Trials Quinapril Placebo (N=1563) (N=579) Incidence Incidence (Discontinuance) (Discontinuance) Headache 5.6 (0.7) 10.9 (0.7) Dizziness 3.9 (0.8) 2.6 (0.2) Fatigue 2.6 (0.3) 1.0 Coughing 2.0 (0.5) 0.0 Nausea and/or Vomiting 1.4 (0.3) 1.9 (0.2) Abdominal Pain 1.0 (0.2) 0.7 Heart Failure Quinapril has been evaluated for safety in 1222 quinapril treated patients. Of these, 632 patients participated in controlled clinical trials. In placebo-controlled trials, discontinuation of therapy because of adverse events was required in 6.8% of patients with congestive heart failure. Adverse experiences probably or possibly related or of unknown relationship to therapy occurring in 1% or more of the 585 patients in placebo-controlled congestive heart failure trials who were treated with quinapril are shown below.

Overdosage

Sourced from openFDA

Doses of 1440 to 4280 mg/kg of quinapril cause significant lethality in mice and rats. No specific information is available on the treatment of overdosage with quinapril. The most likely clinical manifestation would be symptoms attributable to severe hypotension. Laboratory determinations of serum levels of quinapril and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of quinapril overdose. No data are available to suggest physiological maneuvers (eg, maneuvers to change pH of the urine) that might accelerate elimination of quinapril and its metabolites. Hemodialysis and peritoneal dialysis have little effect on the elimination of quinapril and quinaprilat. Angiotensin II could presumably serve as a specific antagonist-antidote in the setting of quinapril overdose, but angiotensin II is essentially unavailable outside of scattered research facilities. Because the hypotensive effect of quinapril is achieved through vasodilation and effective hypovolemia, it is reasonable to treat quinapril overdose by infusion of normal saline solution.

Approval history

Sourced from openFDA
  • Mar 31, 2004ANDAANDA076374Chartwell Rx
  • Mar 2, 2005ANDAANDA076803Chartwell Rx
  • Jun 20, 2006ANDAANDA077690Lupin
  • Aug 24, 2007ANDAANDA078450Aurobindo Pharma
  • Aug 24, 2007ANDAANDA078457Invagen Pharms
  • Apr 20, 2011ANDAANDA201356Invagen Pharms
  • Apr 29, 2013ANDAANDA202725Aurobindo Pharma Ltd
  • Sep 15, 2016ANDAANDA205823Prinston Inc

FDA shortages

View JSON

Reference statistics from the openFDA drug-shortage dataset. For a live view, consult the FDA database directly. Not clinical guidance.

  • Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)Active
    Sponsor: Solco Healthcare US, LLC · Reason: Shortage of an active ingredient
    Updated
  • Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)Active
    Sponsor: Chartwell Molecular Holdings LLC
    Updated
  • Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)Active
    Sponsor: Lupin Pharmaceuticals, Inc. · Reason: Requirements related to complying with good manufacturing practices
    Updated
  • Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)Active
    Sponsor: Solco Healthcare US, LLC · Reason: Shortage of an active ingredient
    Updated
  • Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)Active
    Sponsor: Chartwell Molecular Holdings LLC
    Updated
  • Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)Active
    Sponsor: Lupin Pharmaceuticals, Inc. · Reason: Requirements related to complying with good manufacturing practices
    Updated
  • Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)Active
    Sponsor: Solco Healthcare US, LLC · Reason: Shortage of an active ingredient
    Updated
  • Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)Active
    Sponsor: Chartwell Molecular Holdings LLC
    Updated
  • Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)Active
    Sponsor: Lupin Pharmaceuticals, Inc. · Reason: Requirements related to complying with good manufacturing practices
    Updated
  • Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)Active
    Sponsor: Solco Healthcare US, LLC · Reason: Shortage of an active ingredient
    Updated
  • Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)Active
    Sponsor: Chartwell Molecular Holdings LLC
    Updated

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
7,946 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Fall90511%
  2. 2Pain7589.5%
  3. 3Hypotension7169.0%
  4. 4Constipation7129.0%
  5. 5Balance Disorder6418.1%
  6. 6Cognitive Disorder6317.9%
  7. 7Orthostatic Hypotension6217.8%
  8. 8Sedation5767.2%
  9. 9Mobility Decreased5436.8%
  10. 10Depressed Level Of Consciousness5356.7%
  11. 11Sedation Complication5356.7%
  12. 12Toxicity To Various Agents5326.7%
  13. 13Blood Calcium Decreased5236.6%
  14. 14Dyspnoea5196.5%
  15. 15Creatinine Renal Clearance Decreased5156.5%

Literature

View JSON

Recent PubMed references pinned to Quinapril as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

Clinical trials

View JSON

The 10 most recently updated of 33 ClinicalTrials.gov registrations naming Quinapril as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Structural analogs

View JSON

Ranked by 2D fingerprint (Tanimoto) similarity over PubChem structures. Structural proximity only — not a claim of therapeutic equivalence.

Frequently asked questions

How does Quinapril work?
Mechanism-of-action classes: Angiotensin-converting Enzyme Inhibitors; Neprilysin Inhibitors.
What is Quinapril used for?
According to FDA labeling, Quinapril carries indications including: Hypertension Quinapril tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What class of drug is Quinapril?
Quinapril is classified as ACE inhibitors, plain, Angiotensin Converting Enzyme Inhibitor, Angiotensin-converting Enzyme Inhibitors, Neprilysin Inhibitors, Decreased Blood Pressure, Decreased Bradykinin Degradation, Decreased Intravascular Volume, Decreased Mineralocorticoid Secretion, Decreased Renal K+ Excretion, Increased Renal Na+ Excretion, Renal Arterial Vasodilation.
What are the brand names for Quinapril?
Quinapril is marketed under brand names including Accupril, Accuretic.
What are the contraindications for Quinapril?
Quinapril labeling lists contraindications including: Quinapril tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Quinapril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril).. Always consult the full prescribing information and a clinician.
Note. Data for quinapril is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients